James R. Meyers's most recent trade in Sangamo Therapeutics Inc was a trade of 50,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 12, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Sangamo Therapeutics Inc | James R. Meyers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2025 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Sangamo Therapeutics Inc | James R. Meyers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2025 | 25,000 | 99,600 (0%) | 0% | 0 | Common Stock | |
| CytomX Therapeutics Inc | James R. Meyers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2025 | 38,000 | 38,000 | - | - | Stock Option (Right to Buy) | |
| Sangamo Therapeutics Inc | James R. Meyers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2024 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Sangamo Therapeutics Inc | James R. Meyers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2024 | 25,000 | 74,600 (0%) | 0% | 0 | Common Stock | |
| Arbutus Biopharma Corp | James R. Meyers | Director | 23 May 2024 | 67,000 | 67,000 | - | - | Stock Option (Right to Buy) | ||
| CytomX Therapeutics Inc | James R. Meyers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2024 | 38,000 | 38,000 | - | - | Stock Option (Right to Buy) | |
| CytomX Therapeutics Inc | James R. Meyers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Sangamo Therapeutics Inc | James R. Meyers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 27,750 | 27,750 | - | - | Stock Option (Right to Buy) | |
| Sangamo Therapeutics Inc | James R. Meyers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 13,900 | 49,600 (0%) | 0% | 0 | Common Stock | |
| Arbutus Biopharma Corp | James R. Meyers | Director | 24 May 2023 | 55,000 | 55,000 | - | - | Stock Option (Right to Buy) | ||
| CytomX Therapeutics Inc | James R. Meyers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Arbutus Biopharma Corp | James R. Meyers | Director | 25 May 2022 | 41,000 | 41,000 | - | - | Stock Option (Right to Buy) | ||
| Sangamo Therapeutics Inc | James R. Meyers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2022 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Sangamo Therapeutics Inc | James R. Meyers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2022 | 12,500 | 35,700 (0%) | 0% | 0 | Common Stock | |
| CytomX Therapeutics Inc | James R. Meyers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2021 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Arbutus Biopharma Corp | James R. Meyers | Director | 03 Jun 2021 | 22,000 | 22,000 | - | - | Stock Options | ||
| Sangamo Therapeutics Inc | James R. Meyers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 16,400 | 16,400 | - | - | Stock Option (Right to Buy) | |
| Sangamo Therapeutics Inc | James R. Meyers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 8,200 | 23,200 (0%) | 0% | 0 | Common Stock |